Article Details

J&J focuses on newer meds to offset Stelara patent cliff | BioPharma Dive

Retrieved on: 2024-01-25 03:28:39

Tags for this article:

Click the tags to see associated articles and topics

J&J focuses on newer meds to offset Stelara patent cliff | BioPharma Dive. View article details on hiswai:

Excerpt

Johnson & Johnson CEO Joaquin Duato sold 2023 as a “remarkable year” on an earnings call with investors Tuesday. But the pharmaceutical giant faces ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo